Clinical Oncology


A Manual for Students and Doctors

Edited under the auspices of the International Union Against Cancer

Second Edition
Fully revised and enlarged

[&] Clinical Oncology

R73 C643=2



MX

Edited under the auspices of the International Union Against Cancer

Second Edition
Fully revised and enlarged

With 31 Figures

信蔵专用章

Springer-Verlag
'Berlin Heidelberg New York 1978

vagnono isomit

643-2 Midde of the Same and Doctors

UICC

3, rue du Conseil-Général 1205 Geneva Switzerland

Telephone (022) 20 18 11 Telegraph Cancerunion, Geneva

ISBN 3-540-08868-7 Springer-Verlag Berlin Heidelberg New York ISBN 0-387-08868-7 Springer-Verlag New York Heidelberg Berlin

ISBN 3-540-05851-6 1. Auflage Springer-Verlag Berlin Heidelberg New York ISBN 0-387-05851-6 1st Edition Springer-Verlag New York Heidelberg Berlin

Library of Congress Cataloging in Publication Data. International Union Against Cancer. Clinical oncology. First ed. published in 1973 by the Committee on Professional Education of the International Union Against Cancer. Bibliography: p. Includes index. 1. Oncology. I. International Union Against Cancer. Committee on Professional Education. Clinical oncology. II. Title. [DNLM: 1. Neoplasms. QZ200.3 1615c]. RC261.157. 1978. 616.9'92

This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically those of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying machine or similar means, and storage in data banks. Under § 54 of the German Copyright Law where copies are made for other than private use, a fee is payable to the publisher, the amount of the fee to be determined by agreement with the publisher.

© by Springer-Verlag Berlin Heidelberg 1973, 1978 Printed in Germany

The use of general descriptive names, trade names, trade marks, etc. in this publication, even if the former are not especially identified, is not to be taken as a sign that such names, as understood by the Trade Marks and Merchandise Marks Act, may accordingly be used freely by anyone.

Typesetting, printing and bookbinding: Oscar Brandstetter, Wiesbaden, 2121, 3140 - 543210

The UICC wishes to express its particular gratitude to the Swiss Cancer League whose financial assistance made the work of revision and enlargement of this Second Edition possible.

Since of the Milk manager beautiful the Lorente

f Kemeth W. S. . (Australia)

First Edition edited by the UICC Committee on Professional Education (1966–1970 and 1970–1974)

Umberto Veronesi, Chairman (Italy)
Felipe Alva-Ortega (Mexico)
† Marcel Dargent (France)
Ismail El Sebai (Egypt)
Arthur Jones (UK)
Hanna Kolodziejska (Poland)
A. Hamblin Letton (USA)

Kunio Oota (Japan)
Boris E. Peterson (USSR)
Bruno Salvadori (Italy)
† Moacyr Santos-Silva (Brazil)
Charles D. Sherman Jr. (USA)
† Kenneth W. Starr (Australia)
Richard J. Walton (Canada)

† Deceased

Second Edition revised and enlarged by Members of the UICC Manual Revision Committee

Charles D. Sherman Jr., MD (Chairman, Manual Revision Committee)
Clinical Professor of Surgery, University of Rochester Medical
School, Rochester, N. Y., USA

Ismail Elsebai, MD

Professor of Surgical Oncology, Dean of the National Cancer Institute, Cairo University, Cairo, Egypt

François Eschwege, MD

Associate Professor of Therapeutic Radiology, Institut Gustave-Roussy, Villejuif, France

Ivo Padovan, MD, DSc

Professor of Otorhinolaryngology, University of Zagreb, Head of the Department of Otolaryngology and Cervical Facial Surgery, Zagreb, Yugoslavia

Bruno Salvadori, MD

Professor of Surgical Pathology, Director of Division of Clinical Oncology, National Cancer Institute, Milan, Italy

Carl Gottfried Schmidt, MD

Professor of Medical Oncology, Chairman of the West German Tumor Center, University of Essen, Essen, Fed. Rep. of Germany

Umberto Veronesi, MD (Chairman, UICC Cancer Education Programme)

Professor of Surgical Pathology, Director General of the National Cancer Institute, Milan, Italy

此为试读,需要完整PDF请访问: www.ertongbook.com

Preface to the Second Edition

The outstanding success of the First Edition and the expansion of our knowledge about cancer over the 5 years since its publication have led to the decision to publish a Second Edition which has been fully revised, rewritten and enlarged by the addition of several sections. The First Edition was translated into Italian, Japanese, Polish, and Serbo-Croat and it is expected that additional translations (French, German, Spanish, Portuguese, etc.) will make this Second Edition a truly international basic cancer Manual.

The Revision Committee is convinced that all students and general physicians should know: (a) the important basic aspects of cancer; (b) some details of the most common cancers; and (c) a few important points about the less common cancers. An attempt has been made to strengthen Part I, General Aspects, which is considered to be the most important part of the Manual for the world's physicians. However, the most common cancers in one part of the world are not necessarily the same in other parts and it is planned to work with local groups to produce adaptations and translations as seem appropriate. In particular, the UICC is anxious to work with local, national, and international committees to help improve the educational experience of students and general physicians in the geographic areas in question. Regional Conferences held by the UICC in Latin America, Asia and the Middle East have resulted in initial plans to accomplish this aim.

As one aspect of its Professional Education Programme, the International Union Against Cancer has laid particular stress on the need for *improved organization* of cancer education in the world's medical schools. One method suggested to attain this objective is the establishment of a separate department (chair) of oncology, which has, as one of its responsibilities the coordination and integration of cancer education both in the preclinical and clinical years; an alternative is an interdepartmental committee of basic and clinical faculty.

More than any other area of medicine, oncology demands the integration of basic and clinical sciences, since the clinical oncologist of today must know and use a great deal of basic science—carcinogenesis, epidemiology, screening principles, cell biology and metabolism, cytokinetics, pharmacology of cancer chemotherapy, basic principles of surgery and radiation therapy, etc. In order to avoid gaps, fragmentation and unnecessary duplication and also to develop appropriate teaching

materials and experiences, it is essential to prepare a broad-based educational plan. With good planning and careful execution, an integrated cancer programme can reduce the curriculum time necessary to accomplish this objective and yet do a better job. Indeed, the integrated cancer committee can be a driving force in improving the medical school's educational programme and also serve as a stimulus and example to othes departments. It is hoped that this Manual will be an important resource in every medical school.

The Manual Revision Committee 1978 of the UICC

Acknowledgements

This Manual could not have been written without the unselfish help of many friends and colleagues whose work deserves great credit. In particular thanks should be given to: Dr. J. BENNETT, who reviewed various sections on medical oncology; Dr. N. EL BOLKAINY, who revised the section on pathology; Drs. D.K. Hossfeld and S. Seeber, who collaborated in the sections on leukæmias and lymphomas; Dr. S. MONFARDINI, who revised the section on chemotherapy; Drs. G.T. O'CONOR, D. E. HENSON, and M. E. McClure, who were responsible for developing Part III; Dr. J. STAROBINSKI, who revised the section dealing with the eye; Dr. P.A. Voûte, who revised the section on childhood tumours; the late Dr. J. WAKEFIELD, who contributed to the section on . public education; Dr. G.P. WARWICK, who produced the appendix on comprehensive cancer centres; and Dr. A. WINKLER, who contributed the appendix on cancer registries.

Thanks should also be given to those who contributed to the First Edition of this Manual and especially those who gave advice and assistance in the revision work.

The Committee would like to express its appreciation to Mr. D. W. REED, who acted as Committee Secretary and provided editorial assistance.

Finally, gratitude is extended to the Publishers for their patience in meeting exacting demands.

Preface to the First Edition of the bear and the W treatment of car on the minimum at the Margael that he revised

There can be no doubt that a knowledge of cancer is becoming of increasing importance to doctors throughout the world. The changing patterns of disease incidence, following changes in living standards and public health services and in medial diagnosis and treatment, reveal the importance of neoplastic disorders as causes of morbidity and mortality. If doctors are to recognize these conditions at the earliest opportunity and advise on the treatment, they must be familiar not only with clinical appearances but with the scientific principles on which the management is based. These are so important that they must be assimilated during undergraduate medical education and become an integral part of the doctor's professional equipment.

The clinical study of a neoplastic disorder has usually been related to its site of appearance in the body, and its treatment has been the concern of organ- or system-specialists. This has tended to obscure the fundamental principles of growth disorder which are common to many varieties of tumours. A unified approach of clinical oncology can recognize common features and highlight diversity as a stimulus to further investigation. It is at the same time becoming increasingly recognized that neoplasia is a multidisciplinary problem, requiring the collaboration of many specialists: physicians, surgeons, radiotherapists, chemotherapists, pathologists, immunologists, epidemiologists, and many varieties of research workers. But the fate of the individual patient with cancer is often determined by the first doctor he consults, and this further emphasizes the importance of sufficient caucation in oncology at all stages of medical training.

The Committee on Professional Education of the International Union Against Cancer has therefore prepared a Manual incorporating accounts of those aspects of neoplastic disorders which are likely to be important to a practising physician in any part of the world. The incidence of various tumours varies considerably with geography and other factors; but in this volume an account will be found firstly of the general principles which underlie the processes of growth disorder, and later the principles of treatment of the commoner tumours. This conspectus of neoplastic disorders is commended for the use of undergraduate medical students during their clinical period, and for doctors during their general professional training. It is hoped that it will also be of value to family

physicians as an initial and rapid reference source.

While principles remain, rapid advances are occurring in the methods of treatment of cancer, and it is intended that the Manual shall be revised regularly in an attempt to conform with the best of current methods of treatment. The Committee on Professional Education would be glad to have comments of readers, both medical students and specialist teachers, on how these aims can best be achieved

ใดราชมายสายเกราะที่ เพื่อสายเป็นสายเลือน และ และเกียร์แก้เลือน ในเกิดอย่า ก็บบายเลือน เป็นเลือน เมื่อราย

The Committee on Professional 1972 Education of the UICC

9	n' - arbraidogo l'alla de la comparación de la c	
	Part I. General aspects	1
	Mass specimis hill city de com	
	introduction and overview	3
	Induction phase	<i>3</i>
	<i>In-situ</i> phase	4
	Phase of invasion	5
	Phase of dissemination	<i>5</i>
	Conclusion)
	Lpideimology	6
	incidence and mortanty.	6
	Actiology	0
	Radiation	1
	Chemical substances 1	3
	Iatrogenic chemical factors	5
	Toloutal material	6
	Parasites	21
		21
1	Occupational factors in carcinogenesis	22
1	Genetic factors	25
	Immune deficiency and cancer	27
	Pathology	28
		28
	Classification	28
	Tumour structure	31

Grading of cancer who have been supplied to be a supplied to the control of Clinicopathological correlations who have been supplied to the control of the co

In-situ and precancerous lésions

Local recurrences and metastases

Natural history of cancer

Tumour growth

37.

38

41

43,

44

48

. 45

nodeupand49°

Multiple-primary cancers Effects of treatment on natura Factors bearing on prognosis. Causes of death Spontaneous cure Mass screening and early detection Diagnosis	l history				. 1 MHS		. 50 . 51 . 52 . 53
History		•	iter	•	1 (2) 1 (0) 1 (0)		. 59 . 60 . 61
Evaluation of the extent of disease Clinical staging Pathological staging					i de		. 66
Principles of treatment	roach to	cand	cer th	nera	py .		. 70 . 72 . 75 . 75 . 81 . 85 . 94
Psychological aspects The physician's attitude to car The patient's attitude to his ca The doctor-patient relationshi The special problems of the "c Education of the public about Prognosis	ncer	atier	it		. 110 - 211 - 211	MING RESE OF U OF U SHOP SHOP	. 105 . 106 . 107 . 108
Part II. Cancers of specific sites .			0.35 - 11				. 117
Introduction					FI >		

Skin excluding melanoma	119
Malignant melanoma	123
Head and neck	128
Lips, oral cavity and oropharynx	128
Lip	133
Tongue	134
Buccal mucosa	136
Floor of the mouth	137
Gums	138
Palate	139
Tonsils	140 142
Paranasal sinuses	142
Larynx	144
Hypopharynx	147
Piriform sinus	147
Postcricoid area and posterior wall.	148
Salivary glands	150
Major salivary glands	150
Minor salivary glands	152
Jaw	152
Epulis	153
Odonotomes	153
Adamantinoma	153
Central tumours of the jaw	154
Thyroid	155
Eye	159
Type	1.00
Lung	162
Alimentary tract	166
	166
	168
Danageas	172
Liver	174
	175
Colon, rectum and anus. 2012 descend on the controlled until	176
Breast.	181
	400
Female genital organs	189
•	

	Uterine cervix		• 17					. 8.1		ДЬ,	31,		THE	ш.			189
	Endometrium							ì									194
	Choriocarcinoma									. 198					•		197
										•				31	ŀ		198
	Vagina Vulva															ď	201
	Vulva			7								٠.		. 4			201
Mal	e genital organs																205
	Transition of the second													119	٠,		205
	Penis									1 12	H.	1		4			207
617																	200
	nary tract													PS.	٠	٠	209
ΨI,	Kidney, renal pelvis, u	iret	er										12.	0.1			209
41	Renal-cell carcino	ma												b		ì	209
14,	Carcinoma of the	ren	al p	pel	vis								ar.	rdo	•		210
ship	Nephroblastoma (W_{1}	ms	tı	ım	ou	r)										211
	Bladder	٠.								1.6							211
	Prostate												19				213
Con	tral nervous system.																215
Cen																	
150	Glial tumours			$\hat{\epsilon}^{ij}$	•				٠					4	٠.		215
	Tumours of the memb	orar	ies				Ţ							. 1		. 1	216
	Émbryoplastic tumour																217
	Mesenchymal tumours	s.					٠.										218
Dor	ie													11,45			221
DOI																٠	
	Myeloma				¥/ L			•							٠.	٠	221
	Chondrosarcoma .														141	٠	221
	Soft-tissue sarcomas					*				٠.				. •			222
Lyn	nphomas			٠	•			٠.								ä	225
	Hodgkin's disease .													741	61/	13.11	226
	Non-Hodgkin lympho	ma	S .						į.								231
Jul.																	227
Leu	kæmias			* ,	٠	*	*		÷ ^,	•		•		. *		J.	237
Chi	ldhood cancers													17.3	on ph	1.1	243
	Nephroblastoma, Wili	ns'	tur	no	ur	٧.,						- 1		- gJa	12	÷	247
	Neuroblastoma, symp	ath	icol	ola	sto	ma	ı			ł.			Pyra	1.1	ol	0	247
	Rhabdomyosarcoma															,	248
	Retinoblastoma															.13.	
	Bone tumours												٠, .	14113			251
	Conclusion											. 16	. 14	14175		0118	251 251

P rt III. Basic science research of imminent	253
in pact on clinical oncology	
Introduction	254
Virology	255
Biology	257
Immunotherapy.	261
Biological chemistry	263
Biophysics	266
References	267
Appendices	277
Appendices .	270
1. The International Union Against Cancer - Past and present .	
2. Cancer patient information systems	288
3. The role of comprehensive cancer centres in cancer control	290
4. Evaluation of response to treatment	
5 Suggested further reading	29

Part I. General aspects

fort I. General aspects

Introduction and overview

In the past, most clinicians have focused their interest on the end stage of human cancer, i.e. diagnosis and treatment of the patient with an established cancer, usually (in over 50% of cases) progressing fairly rapidly to a terminal situation. With new knowledge, clinical oncologists of the next few years will need to have a much broader and more comprehensive view of cancer as an extremely long-term process usually lasting many years (see Fig. 1). In particular, clinicians will have to have a better understanding of "preventive oncology".

Fig. 1. Modern viewpoint of cancer as a long-term process

Induction phase	In-situ phase	Invasion phase	Dissemination phase
Up to 15-30 years	5-10 years	1-5 years	1-5 years
			f many concepts with importan

Induction phase

Looking at all the causes of cancer in man that have so far been identified with certainty, the induction phase usually lasts 15-30 years (see Fig. 1). Currently, we still cannot identify with certainty the causes of most cancers, but epidemiologists today feel that environmental factors probably account for about 70-80% of human cancers. It usually takes many years of exposure to a carcinogen before the progressively severe dysplasia becomes a definite cancer. The exceptions to this are: (a) radiation-induced leukæmias (where the induction phase may be as short as 2 years); and (b) the genetically determined cancers of infancy (in which cancer is present at birth or shortly thereafter).

Obviously, not everyone who is exposed to a carginogen gets cancer. Among the factors which help to determine who does get cancer are the following: the nature, amount and concentration of the carcinogen; the site or sites at which it acts; the duration of exposure; the presence of other carcinogens or co-carcinogens; and individual or tissue susceptibility.